Kymera Therapeutics
KYMR · Nasdaq · United States
Share price · KYMR
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when KYMR's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 4 Nov 2026+7.2%
Nothing announced by KYMR that day or the session before.
- 30 Oct 2026+3.3%
- 26 Jun 2026-7.2%
- 25 Jun 2026+16.6%
- 22 Jun 2026+10.0%
Nothing announced by KYMR that day or the session before.
- 2 Jun 2026-9.1%
Nothing announced by KYMR that day or the session before.
- 8 Dec 2025+41.5%
Share of unusual movement by asset
For each asset, the share of KYMR's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | STAT6Small molecule | Atopic DermatitisAsthma |
Discontinued programmes (1)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (2)
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $0 | $129M | $373M+ $598M short-term inv. | $132M-$78M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $65M | $119M | $124M+ $567M short-term inv. | $61M-$54M operating cash flow | report ↗ |
| 2026-Q1 | $34M | $98M | $1.6B+ $507M short-term inv. | $69M-$89M operating cash flow | report ↗ |
| 2025-Q3 | $2.8M | $74M | $113M+ $393M short-term inv. | $82M-$27M operating cash flow | report ↗ |
| 2025-Q2 | $11M | $78M | $336M+ $330M short-term inv. | $77M-$60M operating cash flow | report ↗ |
| 2025-Q1 | $22M | $80M | $90M+ $373M short-term inv. | $66M-$79M operating cash flow | report ↗ |
| 2024-Q3 | $3.7M | $60M | $111M+ $439M short-term inv. | $62M-$50M operating cash flow | report ↗ |
| 2024-Q2 | $26M | $59M | $68M+ $442M short-term inv. | $42M-$43M operating cash flow | report ↗ |
| 2024-Q1 | $10M | $49M | $94M+ $427M short-term inv. | $49M-$40M operating cash flow | report ↗ |
| 2023-Q3 | $4.7M | $48M | $81M+ $277M short-term inv. | $53M-$32M operating cash flow | report ↗ |
| 2023-Q2 | $17M | $46M | $52M+ $315M short-term inv. | $39M-$35M operating cash flow | report ↗ |
| 2023-Q1 | $9.5M | $42M | $50M+ $347M short-term inv. | $41M-$44M operating cash flow | report ↗ |
| 2022-Q3 | $9.6M | $44M | $156M+ $326M short-term inv. | $43M-$34M operating cash flow | report ↗ |
| 2022-Q2 | $12M | $41M | $77M+ $315M short-term inv. | $40M-$39M operating cash flow | report ↗ |
| 2022-Q1 | $9.6M | $36M | $34M+ $387M short-term inv. | $37M-$40M operating cash flow | report ↗ |
| 2021-Q3 | $20M | $38M | $157M+ $380M short-term inv. | $29M-$37M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $39M | $317M | $357M+ $491M short-term inv. | $78M-$233M operating cash flow | report ↗ |
Kymera Therapeutics reported FY2025 revenue of $39.21M, down 16.7% YoY, and R&D spend of $316.57M, up 31.8% YoY. Net loss for the year was $311.35M. The company ended the period with $357.01M in cash and equivalents and separately reported approximately $1.6 billion in cash, cash equivalents, and investments as of December 31, 2025, supporting a cash runway into 2029.
Pipeline updates included the ongoing KT-621 BROADEN2 Phase 2b trial in atopic dermatitis with data expected by mid-2027, the BREADTH Phase 2b asthma trial with data expected in late-2027, and initiation of the KT-579 Phase 1 healthy volunteer trial with data expected in 2H26. The company also received Fast Track designation for KT-621, completed a $602 million underwritten equity offering with gross proceeds of approximately $692 million, and appointed Neil Graham as Chief Development Officer.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $47M | $240M | $120M+ $368M short-term inv. | $56M-$195M operating cash flow | report ↗ |
| 2023-FY | $79M | $189M | $110M+ $265M short-term inv. | $37M-$103M operating cash flow | report ↗ |
| 2022-FY | $47M | $164M | $68M+ $339M short-term inv. | $39M-$153M operating cash flow | report ↗ |
| 2021-FY | $73M | $137M | $48M+ $394M short-term inv. | $25M-$129M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 2 purchases ($172.5M), 274 sales ($473.3M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-01 | Mainolfi Nello · director, Chief Executive Officer | Option exercise | 30,000 | $2.08 | $62K | Form 4 |
| 2026-10-01 | Mainolfi Nello · director, Chief Executive Officer | Open-market sale | 3,525 | $111.44 | $393K | Form 4 |
| 2026-10-01 | Mainolfi Nello · director, Chief Executive Officer | Open-market sale | 5,506 | $112.42 | $619K | Form 4 |
| 2026-10-01 | Mainolfi Nello · director, Chief Executive Officer | Open-market sale | 4,876 | $113.24 | $552K | Form 4 |
| 2026-10-01 | Mainolfi Nello · director, Chief Executive Officer | Open-market sale | 7,601 | $114.43 | $870K | Form 4 |
| 2026-10-01 | Mainolfi Nello · director, Chief Executive Officer | Open-market sale | 8,230 | $115.40 | $950K | Form 4 |
| 2026-10-01 | Mainolfi Nello · director, Chief Executive Officer | Open-market sale | 262 | $116.12 | $30K | Form 4 |
| 2026-10-01 | Mainolfi Nello · director, Chief Executive Officer | Option exercise (derivative) | 30,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 254 reporting institutions held 96.3M shares ($7.0B, 112.8% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | FMR LLC | 11,699,950 | $974.5M |
| 2 | BAKER BROS. ADVISORS LP | 8,657,242 | $721.1M |
| 3 | Avoro Capital Advisors LLC | 7,474,747 | $622.6M |
| 4 | BVF INC/IL | 5,502,710 | $458.3M |
| 5 | BlackRock, Inc. | 5,060,876 | $421.5M |
| 6 | Atlas Venture Life Science Advisors, LLC | 4,578,008 | $381.3M |
| 7 | WELLINGTON MANAGEMENT GROUP LLP | 3,889,687 | $324.0M |
| 8 | Siren, L.L.C. | 3,186,830 | $265.4M |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | 2,880,324 | $239.9M |
| 10 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2,874,056 | $239.4M |
| 11 | STATE STREET CORP | 2,389,767 | $199.0M |
| 12 | Capital Research Global Investors | 1,673,275 | $139.4M |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | 1,645,350 | $137.1M |
| 14 | Driehaus Capital Management LLC | 1,043,583 | $86.9M |
| 15 | UBS Group AG | 1,023,852 | $85.3M |